Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Breast Cancer: Update Bulletin [December 2014]

Product Code:
596200329
Release Date:
November 2014
Format:
PDF
Price:
£1,140

Gain new KOL insights on the latest events happening in Breast Cancer: Pfizer’s cyclin-dependent kinase (CDK) inhibitor palbociclib; PALOMA-1 trial; Novartis’ LEE011 and Eli Lilly’s ademaciclib; MARIANNE trial; Roche’s Kadcyla (trastuzumab emtansine); Perjeta (pertuzumab); TANIA, IMELDA trials; Roche’s Avastin (bevacizumab) 

Highlights from this event update bulletin

  • What important question will the MARIANNE trial leave unanswered and how will oncologists interpret the data?
  • What opportunity exists for Roche to improve the uptake of Perjeta in the neoadjuvant setting?
  • Will Roche’s Avastin make a comeback in the treatment of breast cancer?
  • What is the likelihood the FDA will approve Pfizer’s palbociclib based on data from phase II PALOMA-1 trial?
  • What will ultimately differentiate the CDK inhibitors under development for breast cancer by Pfizer, Novartis and Eli Lilly?

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved